Allergan

Type	Public company
Traded as	NYSE: ABBV S&P 100 component S&P 500 component
Industry	Biopharmaceutical
Founded	2013 (2013)
Founder	S Nikhil Kumar
Headquarters	North Chicago, Illinois, U.S.
Area served	Worldwide (170+ countries)
Key people	Richard A. Gonzalez (Chairman and CEO) Robert Michael (Vice Chairman and President)
Products	Pharmaceutical drugs Humira (adalimumab) Imbruvica (ibrutinib) Venclexta (venetoclax) Zinbryta (daclizumab) Kaletra (lopinavir) Norvir (ritonavir) Mavyret/Maviret (glecaprevir/pibrentasvir) Skyrizi (risankizumab) Rinvoq (upadacitinib)
Revenue	US$56.20 billion (2021)
Operating income	US$17.92 billion (2021)
Net income	US$11.54 billion (2021)
Total assets	US$146.53 billion (2021)
Total equity	US$15.44 billion (2021)
Number of employees	50,000 (Jan 2022)
Website	abbvie.com

Allergan is now part of AbbVie

We discover and develop innovative medicines for tomorrow, while helping people live better lives today.

We offer over 30+ brands treating 60+ conditions from oncology and immunology to aesthetics and eye care. Search our global list of products or filter by therapeutic area.

For detailed contact information visit location pages below.